Dupont Capital Management Corp Travere Therapeutics, Inc. Transaction History

Dupont Capital Management Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 27, 2022	SELL	$23.61 - $30.6 $26,939 - $34,914	-1,141 Reduced 8.13%	12,891 $332,000
Q4 2021 Jan 31, 2022	SELL	$24.34 - $31.17 $136,182 - $174,396	-5,595 Reduced 28.51%	14,032 $436,000
Q3 2021 Nov 03, 2021	SELL	$12.98 - $25.03 $36,006 - $69,433	-2,774 Reduced 12.38%	19,627 $476,000
Q1 2021 Apr 29, 2021	SELL	$23.37 - $31.77 $107,361 - $145,951	-4,594 Reduced 17.02%	22,401 $559,000
Q4 2020 Jan 28, 2021	BUY	$19.17 - $27.87 $517,494 - $752,350	26,995 New	26,995 $736,000

203

85.2M

776K

912K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.4B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.